A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects (RSVP)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)

This was a randomized, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered EDP-938 in adults with RSV infection.

Study Overview

• Status: Completed
• Conditions: Respiratory Syncytial Virus
• Intervention / Treatment: Drug: EDP-938; Drug: Placebo

Detailed Description

Subjects (aged 18 to 75 years, inclusive) with up to 48 hours of upper respiratory tract infection (URTI) symptoms who tested positive for respiratory syncytial virus (RSV) and negative for influenza virus by rapid testing (ie, Rapid Viral Screen). Subjects with stable asthma or chronic obstructive pulmonary disease (COPD) were allowed in the study.

Eighty-two (82) subjects were enrolled in this Phase 2b, randomized, double-blind, placebo-controlled, multicentre study of EDP-938 administered orally for the treatment of acute URTI with confirmed RSV infection in ambulatory adult subjects.

For each subject, the duration of study participation was approximately 2 weeks and consisted of 3 periods: Screening (occurs on Day1), Treatment (5 days), and Follow-up (9 days after last dose).

• Study Type: Interventional
• Enrollment (Actual): 82
• Phase: Phase 2

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, B1900AVG
    • Instituto Medico Platense
• Bulgaria
  • Blagoevgrad, Bulgaria, 2700
    • Multiprofile Hospital for Active Treatment Puls
  • Haskovo, Bulgaria, 6300
    • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases - Haskovo EOOD
  • Kozloduy, Bulgaria, 3320
    • Medical Center Zdrave-1 OOD
  • Veliko Tarnovo, Bulgaria, 5000
    • Medical Center Tara OOD
  • Sofia-Grad
    • Sofia, Sofia-Grad, Bulgaria, 1431
      • Diagnostic and Consulting Center Aleksandrovska EOOD
    • Sofia, Sofia-Grad, Bulgaria, 1510
      • Medical Center Hera
• New Zealand
  • Hamilton, New Zealand, 3200
    • Lakeland Clinical Trials - Waikato
  • Rotorua, New Zealand, 3010
    • Lakeland Clinical Trials
• Poland
  • Ostróda, Poland, 14-100
    • Specjalistyczny Osrodek Leczniczo-Badawczy Zbigniew Zegota
  • Malopolskie
    • Tarnów, Malopolskie, Poland, 33-100
      • ALERGO-MED Specjalistyczna Przychodnia Lekarska Sp. z.o.o
• South Africa
  • Western Cape
    • Worcester, Western Cape, South Africa, 6850
      • Clinical Projects Research SA pty Ltd
• Ukraine
  • Kyiv, Ukraine, 3035
    • Medical Center of LLC Preventclinic
  • Kyiv, Ukraine, 4050
    • Limited Liability Company Medical Center Consilium Medical
  • Kyiv, Ukraine, 3035
    • City Outpatient Clinic #9
  • Ivano-Frankivsk
    • Ivano-Frankivs'k, Ivano-Frankivsk, Ukraine, 76014
      • Communal Non-Profit Enterprise City Clinical Hospital #1 of Ivano-Frankivsk City Council
  • Poltavs'ka Oblast
    • Poltava, Poltavs'ka Oblast, Ukraine, 36039
      • Municipal Enterprise The 1st City Clinical Hospital of Poltava City Council
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35209
      • Central Alabama Research
    • Pelham, Alabama, United States, 35124
      • Cahaba Research Inc. - Birmingham
  • California
    • Anaheim, California, United States, 92804
      • Saint Joseph's Clinical Research
    • Lomita, California, United States, 90717
      • Torrance Clinical Research Institute
  • Florida
    • Miami, Florida, United States, 33155
      • Miami Clinical Research - ClinEdge - PPDS
  • Nebraska
    • Bellevue, Nebraska, United States, 68005
      • Pioneer Clinical Research LLC
    • Norfolk, Nebraska, United States, 68701
      • Meridian Clinical Research
  • Nevada
    • Las Vegas, Nevada, United States, 89121
      • Clinical Research of South Nevada
  • North Carolina
    • Shelby, North Carolina, United States, 28150
      • Carolina Research Center
    • Wilmington, North Carolina, United States, 28401
      • PMG Research of Wilmington
    • Winston-Salem, North Carolina, United States, 27103
      • Progressive Medicine of the Triad, LLC
  • Texas
    • Lampasas, Texas, United States, 76550
      • FMC Science

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 73 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• An informed consent document must be signed and dated by the subject
• Male or female individuals aged 18 to 75 years, inclusive.
• Up to 48 hours of URTI symptoms with at least one of the following symptoms:

Nasal discharge, nasal congestion, malaise/tiredness, headache, sinus congestion, sneezing, sore throat, hoarseness, cough, shortness of breath, respiratory wheeze, earache, and/or symptoms of fever.

• Positive for RSV infection and negative for influenza virus based on rapid diagnostic.
• Must be willing and able to adhere to the study assessments, visit schedules, prohibitions, and restrictions, as described in this protocol.

Exclusion Criteria:

• SARS-CoV-2 positive within 28 days of Screening or at Screening following signature of full ICF.
• Clinical evidence of a lower respiratory tract infection, as determined by the Investigator.
• Anticipated need for hospitalization or emergency room care within 24 hours of Screening.
• Receipt of systemic antiviral, antibacterial, antifungal, or antimycobacterial therapy within 7 days of Screening and for the duration of the study
• Awareness of concomitant respiratory infections that are viral (other than RSV), bacterial, or fungal, including systemic bacterial or fungal infections, within 7 days of Screening.
• Frailty scale score ≥4 at Screening.
• History of chronic liver disease (eg, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, autoimmune hepatitis, nonalcoholic steatohepatitis, and/or alcoholic liver disease); a history of biliary disease (eg, primary sclerosing cholangitis, cholecystitis, choledocholithiasis); or a history of portal hypertension. A diagnosis of hepatic steatosis (fatty liver) is not exclusionary.
• Heart disease: any congenital heart disease, acute or chronic heart failure, ischemic heart disease, congenital long QT syndrome, or any clinical manifestation resulting in QT interval prolongation.
• Neurological and neurodevelopmental disorders (including disorders of the brain, spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy [seizure disorders], stroke, muscular dystrophy, or spinal cord injury).
• Malignant tumor or history of malignancy that may interfere with the aims of the study or a subject completing the study.
• Prior receipt or the subject is waiting to receive a bone marrow, stem cell, or solid organ transplantation.
• Diagnosis of cystic fibrosis.
• Known positive human immunodeficiency virus, active hepatitis A virus infection, chronic hepatitis B virus infection, and/or current or treated hepatitis C virus infection.
• Prior or planned ileal resection or bariatric surgery.
• Pregnant or nursing female subjects.
• History of alcohol addiction or current heavy alcohol use defined as: >14 standard drinks per week and/or ≥4 standard drinks per occasion for males and >7 standard drinks per week and/or ≥3 standard drinks per occasion for females. A standard drink is 12 oz of beer (5% alcohol), 5 oz table wine (12% alcohol), or 1.5 oz of spirits (40% alcohol).
• Known or suspected, in the opinion of the Investigator, renal disease or renal impairment.
• Twelve-lead ECG demonstrating a QT interval corrected for heart rate according to Fridericia (QTcF) that is >500 msec or other clinically relevant abnormalities as judged by the Investigator at Screening.
• Use of or intention to use excluded or contraindicated medication(s) or supplements, including any medication known to be a moderate or potent inducer or inhibitor of the cytochrome P450 3A4 enzyme, within 14 days prior to Screening and for the duration of the study.
• Receipt of ≥14 days of systemic immunomodulator therapy (eg, oral corticosteroids) within 3 months of Screening.
• Prior to the first dose of study drug and during study participation, the subject has received any vaccine, investigational agent, or biological product within 30 days or 5 times the half-life, whichever is longer. Note: Influenza vaccination within 7 days of Screening is allowed.
• Use of St John's wort within 28 days prior to the first dose of study drug and for the duration of the study.
• History of or currently experiencing a medical condition or any other finding (including laboratory test results) that, in the opinion of the Investigator, might confound the results of the study; pose an additional risk in administering study drug to the subject; could prevent, limit, or confound the protocol-specified assessments; or deems the subject unsuitable for the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: EDP-938; Subjects will take EDP-938 tablets (800 mg) once a day orally for 5 days	Drug: EDP-938; Four tablets daily for 5 days
Placebo Comparator: Placebo; Subjects will take EDP-938 matching placebo tablets once a day orally for 5 days	Drug: Placebo; Four tablets daily for 5 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total Symptom Score (TSS) Area Under the Curve (AUC)	Assessed by the RSV Symptom Diary, including 13 items assessing the severity of RSV-related signs and symptoms. The diary uses a 4-point scale that consists of grading symptoms on a scale of 0 to 3 for each item, where Grade 0 is Absent, Grade 1 is Noticeable, Grade 2 is Bothersome but not preventing activity, and Grade 3 is Bothersome and interfering with activities. TSS is derived daily by summing of the 13 observed symptom grade values from Day 1 through Day 14 to generate the curve for analysis.	Day 1 through Day 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
RSV RNA Viral Load Area Under the Curve (AUC)	RSV RNA viral load as measured in nasopharyngeal swab samples by RT-qPCR on Days 1 (Baseline, time 0), 3, 5, 9, and 14 to generate curve for analysis.	Day 1 through Day 14
Number of Subjects With RSV RNA Viral Load Below Limit of Detection (LOD)	Proportion of patients that have undetectable RSV RNA by qRT-PCR at Days 3, 5, 9 and 14.	Days 3, 5, 9 and 14
Number of Participants With Adverse Events		Day 1 through Day 14

Collaborators and Investigators

• Sponsor: Enanta Pharmaceuticals, Inc
• Collaborators: PPD
• Investigators: Study Director: Scott Rottinghaus, MD, Enanta Pharmaceuticals, Inc

Study record dates

Study Major Dates

• Study Start (Actual): January 22, 2020
• Primary Completion (Actual): January 4, 2022
• Study Completion (Actual): January 4, 2022

Study Registration Dates

• First Submitted: December 3, 2019
• First Submitted That Met QC Criteria: December 10, 2019
• First Posted (Actual): December 12, 2019

Study Record Updates

• Last Update Posted (Actual): October 30, 2023
• Last Update Submitted That Met QC Criteria: October 26, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: RSV
• Additional Relevant MeSH Terms: Infections; Respiratory Tract Diseases; Respiratory Tract Infections
• Other Study ID Numbers: EDP 938-102

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No